Zioptan (Pf) (tafluprost/PF)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Tafluprost, a fluorinated analog of naturally occurring prostaglandin F2alpha (PGF2alpha), is an ocular hypotensive agent.
Tafluprost, a fluorinated analog of prostaglandin F2alpha (PGF2alpha), is an ocular hypotensive agent that is structurally and pharmacologically related to other agents in this class (e.g., latanoprost, travoprost). Like latanoprost and travoprost, tafluprost acts as a selective prostanoid FP receptor agonist. Although the mechanism of action of tafluprost has not been fully elucidated, the drug appears to reduce intraocular pressure (IOP) by increasing uveoscleral outflow.
Tafluprost is an ester prodrug; the drug is rapidly hydrolyzed to its active form (tafluprost acid) by corneal esterases. Tafluprost is a potent FP receptor agonist, with affinity for the receptor that is 12 times that of latanoprost. Tafluprost has negligible affinity for other prostanoid receptors (e.g., DP, EP2, IP, TP).
A reduction in IOP generally occurs approximately 2-4 hours after ocular instillation and reaches maximum effect after 12 hours.
USES: Tafluprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.
Generic name: tafluprost/PF
Pronunciation: (TA-floo-prost)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Zioptan (Pf)
Indications
The following indications are listed for Zioptan (Pf):
- Ocular Hypertension
- Open Angle Glaucoma
Also known as: Chronic Glaucoma, Compensated Glaucoma, Glaucoma Simplex, Increased Intraocular Pressure, Increased Iop, Open-Angle Glaucoma, Raised Intraocular Pressure, Simple Glaucoma.
Dosing
The recommended adult dosage of tafluprost for the treatment of open-angle glaucoma or ocular hypertension is 1 drop of a 0.0015% ophthalmic solution in the conjunctival sac of the affected eye(s) once daily in the evening. Tafluprost should not be administered more frequently than once daily since more frequent dosing may diminish the intraocular pressure (IOP)-lowering effect of the drug.
If the target IOP is not achieved, alternative or additional ocular hypotensive agents may be required. (See Uses: Ocular Hypertension and Glaucoma.)
Tafluprost is applied topically to the eye(s) as an ophthalmic solution.
If the patient is receiving more than one topical ophthalmic drug, the drugs should be administered at least 5 minutes apart.
Tafluprost is available as a preservative-free 0.015-mg/mL (0.0015%) solution packaged in single-use containers; each single-use container has 0.3 mL of solution, corresponding to 0.0045 mg of tafluprost. Because tafluprost ophthalmic solution contains no preservatives, the drug should be used immediately after opening the single-use container; any unused portion should be discarded immediately after administration since sterility cannot be maintained after the container is opened.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
No formal drug interaction studies have been performed. However, no interactions are expected because of limited systemic exposure.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
The manufacturer states there are no known contraindications to the use of tafluprost.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
Adverse ocular effects reported in 2% or more of patients receiving tafluprost ophthalmic solution include conjunctival hyperemia, ocular stinging/irritation, ocular pruritus (including allergic conjunctivitis), cataract, dry eye, ocular pain, eyelash darkening, growth of eyelashes, and blurred vision.
Adverse nonocular effects reported in 2% or more of patients receiving tafluprost ophthalmic solution include headache, common cold, cough, and urinary tract infection.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
Use of tafluprost ophthalmic solution in pediatric patients is not recommended because of potential safety concerns related to increased pigmentation following long-term use. (See Pigmentation under Cautions: Warnings/Precautions.)
Category C. (See Users Guide.)
Teratogenicity, embryolethality, and decreased fetal weight have been demonstrated in animals receiving IV tafluprost. There are no adequate and well-controlled studies using tafluprost in pregnant women. Tafluprost should not be used during pregnancy unless the potential benefits justify the potential risk to the fetus. Women of childbearing potential should use effective contraceptive methods during tafluprost therapy.
Tafluprost and/or its metabolites are distributed into milk in rats; it is not known whether tafluprost and/or its metabolites are distributed into human milk. Because many drugs are distributed into human milk, caution should be exercised when tafluprost ophthalmic solution is administered to a nursing woman.
No overall differences in safety or efficacy have been observed between geriatric patients and younger adults.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.